- Home
- ICMB vs MAIA Comparison
ICMB vs MAIA Comparison
Compare ICMB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICMB | MAIA |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2M | 49.3M |
| IPO Year | 2013 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ICMB | MAIA |
|---|---|---|
| Price | $2.91 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 17.81% | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | $73.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.46 | $0.87 |
| 52 Week High | $3.38 | $3.19 |
Technical Indicators
Market Signals| Indicator | ICMB | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 37.22 |
| Support Level | $2.75 | $1.20 |
| Resistance Level | $2.90 | $1.69 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 0.00 | 10.95 |
Price Performance
Historical ComparisonAbout ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.